Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera. The COVID-19 vaccine maker says it will pay $47.50 per share in cash for